Safety and Efficacy of Dispase and Plasmin in Pharmacologic Vitreolysis

Wang, F; Wang, Z; Sun, Xiaodong; Xu, Xiaoyan; Zhang, X

doi:10.1167/iovs.04-0026

Cited by 52 publications

(37 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this rabbit study, some initial inflammation, along with decreased b-wave amplitudes in the ERG, resolved spontaneously within 7 days [29]. Other studies showed transient inflammation without ERG changes after injection of 1 U and 4 U of Calbiochem streptokinase-plasminogen into the vitreous cavity of rabbits [14,30,31].…”

Section: Discussionsupporting

confidence: 51%

Safety profile of the intravitreal streptokinase-plasmin complex as an adjunct to vitrectomy in the rabbit

Hermel

Mahgoub

Youssef

et al. 2005

Graefe's Arch Clin Exp Ophthalmo

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 51%

Safety profile of the intravitreal streptokinase-plasmin complex as an adjunct to vitrectomy in the rabbit

Hermel

Mahgoub

Youssef

et al. 2005

Graefe's Arch Clin Exp Ophthalmo

View full text Add to dashboard Cite

show abstract

“…The safety profile of intravitreal plasmin in these preclinical trials was excellent, as histological examinations with light and electronic microscopy at doses up to 4 U and with exposure times ranging from 30 min to 1 week did not reveal damages [11,20,37,41,42] . In addition, no functional toxicity was detected by ERG [11,20,45] .…”

Section: Plasminmentioning

confidence: 96%

“…Despite the results of these researches, most experimental studies reported some harmful effects. It has been suggested that dispase could trigger proliferative vitreoretinopathy, cataract, lens subluxation and retinal toxicity [10][11][12][13][14][15][16] .…”

Section: Dispasementioning

confidence: 99%

Review and Perspectives on Pharmacological Vitreolysis

Bandello¹,

Spina²,

Iuliano³

et al. 2013

Ophthalmologica

View full text Add to dashboard Cite

The vitreous is involved in multiple diseases when an incomplete posterior vitreous detachment (PVD) occurs. An incomplete PVD can lead to several pathological conditions. Such visually threatening conditions are traditionally of exclusive surgical interest. In contrast, pharmacological vitreolysis is the effort to reduce or eliminate the pathogenetic role of the vitreous solely by means of drug delivery. Here we aim to review and summarize the evidence available to date about this challenging new approach.

show abstract

“…La inyección intravítrea de 0,4 UI de plasmina ha demostrado en estudios previos ser suficiente para separar el cortex vítreo posterior de la limitante interna, sin toxicidad conocida hasta concentraciones de 3-4 UI (4,17,22,24,25,27).…”

Section: Arch Soc Esp Oftalmol 2008; 83: 77-84unclassified

Vitrectomía enzimática por inyección intravítrea de plasmina autóloga como tratamiento inicial del edema macular diabético difuso

Díaz-Llopis

Udaondo²,

García-Delpech³

et al. 2008

Arch Soc Esp Oftalmol

View full text Add to dashboard Cite

RESUMENObjetivo: Determinar si la inyección intravítrea de plasmina es efectiva en el tratamiento del edema macular diabético difuso (EMDD). Diseño: Estudio piloto prospectivo, comparativo, de intervención, serie de casos. Pacientes: Dieciocho pacientes con edema macular diabético bilateral, recibieron como primera actuación terapéutica una inyección intravítrea de plasmina en un ojo, sirviendo el ojo contralateral como control. Tratamiento: Inyección intravítrea de 0,2 ml de plasmina autóloga bajo anestesia tópica. La plasmina fue obtenida por un metodo simplificado. Principales medidas: Engrosamiento macular central (EMC) medido por tomografía de coherencia óptica (OCT) y agudeza visual (escala LogMAR), al mes y los 3 meses. ABSTRACTPurpose: To determine whether intravitreal injection of plasmin is effective in treating diffuse diabetic macular edema (DDME). Design: A prospective, comparative, interventional case study. Patients: Eighteen patients with bilateral DDME received, as their primary therapeutic treatment, an intravitreal injection of plasmin in one eye, with their contralateral untreated eye serving as a control. Intervention: Intravitreal 0.2 ml of autologous plasmin injected under topical anesthesia. The plasmin was obtained by a simplified method. Main Outcome Measures: Central macular thickness (CMT), determined by optical coherence tomography (OCT), and Best Corrected Visual Acuity (LogMAR), assessed at one and three months of follow-up. Results: All patients completed the 3-month follow-up assessments. Before the injection, the CMT was 525.22 SD 80.12 µm [mean ± standard deviation (SD)] in the eyes to be injected, compared to 525.44 SD 78.13 µm in the control eyes. One

show abstract

Safety and Efficacy of Dispase and Plasmin in Pharmacologic Vitreolysis

Abstract: Intravitreal injection of dispase at 0.025 U or more can induce PVD, but it is not safe. Plasmin (1-4 U) is safer, except for the potential risk of inducing intraocular inflammation.

Cited by 52 publications

References 19 publications

Safety profile of the intravitreal streptokinase-plasmin complex as an adjunct to vitrectomy in the rabbit

Safety profile of the intravitreal streptokinase-plasmin complex as an adjunct to vitrectomy in the rabbit

Review and Perspectives on Pharmacological Vitreolysis

Vitrectomía enzimática por inyección intravítrea de plasmina autóloga como tratamiento inicial del edema macular diabético difuso

Contact Info

Product

Resources

About